NCT01656265View on ClinicalTrials.gov

Study of ARQ 197 in Hepatocellular Carcinoma (HCC)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

ARQ 197

Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.

Trial Locations (1)

Unknown

Kashiwa

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT01656265 - Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter